NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Ondas Holdings And 2 Other Stocks Under $2 Insiders Are Buying

Published 24/05/2024, 12:29
© Reuters.  Ondas Holdings And 2 Other Stocks Under $2 Insiders Are Buying
QRTEA
-
OPK
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by over 600 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Qurate Retail

  • The Trade: Qurate Retail, Inc. (NASDAQ:QRTEA) President/CEO David Rawlinson bought a total of 100,000 shares at an average price of $0.72. To acquire these shares, it cost around $71,878.
  • What's Happening: On May 8, Qurate Retail posted downbeat quarterly sales.
  • What Qurate Retail Does: Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries.
Ondas Holdings
  • The Trade: Ondas Holdings Inc. (NASDAQ:ONDS) Director Joseph V Popolo acquired a total of 100,000 shares at an average price of $0.78. To acquire these shares, it cost around $78,232.
  • What's Happening: On May 15, Ondas Holdings posted in-line loss for its first quarter.
  • What Ondas Holdings Does: Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India.
OPKO Health
  • The Trade: OPKO Health, Inc. (NASDAQ:OPK) 10% owner Frost Gamma Investments Trust acquired a total of 100,000 shares at an average price of $1.27. The insider spent around $126,937 to buy those shares.
  • What's Happening: On May 7, OPKO Health reported worse-than-expected first-quarter financial results.
  • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.
Read This Next: Top 5 Tech Stocks That Could Lead To Your Biggest Gains This Month

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.